Mali Barbi, Medical Oncologist at Northwell Health, shared a post on X:
“The NOUS209 phase 1b/2 results in Nature Medicine mark a shift to true cancer interception.
This ‘off-the-shelf’ vaccine trains T cells to hunt 209 shared neoantigens, stopping precancers before they turn invasive.
The Breakthrough:
- 100% Response: Potent T-cell immunity in every evaluable participant.
- Zero new advanced adenomas detected at 1 year.
- Safe with no intervention-related serious adverse events.
But with the Phase 1/2 cohort being 91% white, Phase 3 must mandate recruitment targets that reflect the true diversity of the Lynch Syndrome population to ensure these breakthroughs are validated for all communities. We must also move beyond colorectal signals to prioritize endometrial cancer interception to shift the standard of care from invasive prophylactic surgeries toward immune-based prevention. Training the immune system to stop cancer before it starts.”
Title: Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
Authors: Anna Morena D’Alise, Jason Willis, Fahriye Duzagac, Michael Hall, Marcia Cruz-Correa, Gregory Idos, Selvi Thirumurthi, Veroushka Ballester, Guido Leoni, Irene Garzia, Laura Antonucci, Lorenzo De Marco, Elisa Micarelli, Nan Deng, Laura Seclì, Sven Gogov, Wenli Dong, Jack Lee, Charles Bowen, Lana Vornik, Araceli Garcia-Gonzalez, Laura Reyes-Uribe, Ellen Richmond, Asad Umar, Powel Brown, Krishna Sinha, Luz Maria Rodriguez, Elisa Scarselli, Eduardo Vilar
Read the Full Article in Nature Medicine.
More posts from Mali Barbi on OncoDaily.